AstraZeneca is giving it's internal service providers a chance to compete with vendors. They've teamed up with Assay Depot to create a virtual exchange to show services available, cost, and quality. They believe this is a great step in finding quicker and efficient way to advance drugs to the market. The exchange hosts 6000 external vendors in addition to in-house AstraZeneca services.
According to Fierce Biotech IT, AstraZeneca's Vice President of Discovery Sciences Mike Snowden stated: "By connecting our internal and external science, the virtual laboratory platform is creating a new approach for our scientists to run experiments with an optimal balance of speed, quality and cost. We look forward to assessing how the virtual laboratory platform impacts and accelerates productivity in the R&D pipeline."
This fall at the Clinical Business Expo, Nicos Zittis, Vendor Qualification Specialist Vendor Strategy & Management, Global Clinical Trial Operations, Merck will be on hand to present Implement a Quality Management Approach to Clinical Vendor Selection at Strategic Clinical Outsourcing. Merck will discuss their process for vendor selection. For more information on this session and the rest of the program, download the agenda. If you'd like to join us this September 18-20 in Boston, register today and mention code XP1725BLOG and save 15% off the standard rate!
What do you think about AstraZeneca creating an exchange to vet potential vendors? Do you think this will contribute to the quality and the rate of their of clinical trials?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.